Our Work
The PI has authored a diverse array of impactful publications, showcasing a multidisciplinary approach to advance drug discovery and delivery in ocular health. Our work includes the development of dual-responsive PNIPAM–chitosan magnetic nanopolymers for targeted drug delivery and the low-temperature synthesis of nickel ferrite nanoparticles with applications in magnetic hyperthermia. We have explored the potential of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for prevalent viral infections, proposing innovative strategies such as using zinc oxide tetrapod nanoparticles for immunotherapy against herpetic infections. Our research spans the evaluation of theranostic agents like gadolinium-doped nickel ferrite nanoparticles, the design of novel drug delivery platforms like DECON, and the investigation of host factors as a strategy to prevent herpes simplex virus-1 infection in the eye. Our studies extend to the development of antiviral aptamers, investigation of CREB3 silencing, and the use of multi-omic approaches for ocular drug discovery. These include novel insights into corneal tissue models, liposome-based antiviral therapies, and the characterization of guinea pigs as models for ocular pathophysiology. This extensive research portfolio reflects a commitment to pioneering solutions for ocular diseases and drug delivery mechanisms.
Projects
01
Activated carbon as novel sustained delivery systems for the delivery of anti-inflammatory molecules to the eye.
​This project involves the use of activated micro-carbons as cell and mucoadhesive sustained delivery systems for the anterior segment of the eye. They will be used to deliver dexamethasone and prednisone for the treatment of ocular inflammation
02
Mesoporous nanomaterials for the treatment of microbial infections in the cornea
This project centers around the development of mesoporous silica and carbon nanomaterials can act as drug reservoirs in the stromal region and prevent herpetic recurrences. These materials only release the drug in the presence of a virus/pathogen of interest making them stimuli specific drug depots.
03
Cell-type specific targeted delivery platforms
The cornea is an immune privileged organ that hosts dozens of cell types with varying functionalities. Our current motto is to develop targeting systems that can individually recognize various cell types within the corneal space and deliver drug payloads to them. This ensures lower toxicity and decreased drug concentrations necessary for the treatment of corneal pathologies.
04
Ocular Disease Modeling through Targeted Organelle Ablation in the eye
In the project, utilizing innovative approaches, we aim to selectively decimate specific organelles within distinct cell types, enabling the creation of finely tuned disease models. Our approach will ensure a controlled and reproducible means to induce highly specific ocular disease models and provide a valuable platform for fellow researchers to explore and advance therapeutic interventions for disorders within the intricate landscape of ocular health.
